Related Experiment Video
Updated: Jul 12, 2025

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
TACkling Cancer by Targeting Selective Protein Degradation
María Del Mar Noblejas-López1,2, David Tébar-García1,2, Raquel López-Rosa1,2
1Centro Regional de Investigaciones Biomédicas (CRIB), Campus de Albacete, Universidad de Castilla-La Mancha, 02008 Albacete, Spain.
Targeted protein degradation offers new cancer therapies by degrading disease proteins. Technologies like PROTACs and LYTACs are advancing experimental treatments toward clinical use.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Targeted protein degradation is a novel therapeutic strategy for cancer treatment.
- Degrader drugs offer advantages over traditional inhibitors by facilitating protein clearance.
- These drugs can be engineered to cross cell membranes and enhance degradation pathways.
Purpose of the Study:
- To review current trends in targeted protein degradation technologies.
- To highlight the progress of TACnologies towards clinical applications.
- To discuss various TACnologies including PROTAC, PHOTAC, CLIPTAC, AUTAC, ATTEC, LYTAC, and DUBTAC.
Main Methods:
- Literature review of targeted protein degradation strategies.
- Analysis of TACnologies and their mechanisms of action.
- Examination of experimental development and clinical progress.
Main Results:
- TACnologies demonstrate diverse strategies for targeted protein degradation.
- PROTACs, PHOTACs, CLIPTACs, AUTACs, ATTECs, LYTACs, and DUBTACs represent key advancements.
- These technologies show significant potential for cancer therapy.
Conclusions:
- Targeted protein degradation represents a promising frontier in cancer therapeutics.
- The reviewed TACnologies are progressing rapidly from experimental stages to potential clinical use.
- Further development of these innovative approaches could revolutionize cancer treatment.
More Related Videos
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Tumor Immunotherapy
Drugs that Stabilize Microtubules
Inhibition of Cdk Activity